Physician profile
Devina Mehta
NPI 1760042196
$4,049.11
in general payments reported to CMS, 2019-2025
26 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.83 · 2024: $1,667 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.47 |
| Education | $208.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $482.32 | 2023-2025 | Zoryve |
| Abbvie INC. | $382.34 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $356.43 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $333.84 | 2024-2025 | |
| Ucb, INC. | $327.93 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $320.16 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $309.91 | 2024-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $210.70 | 2025 | Tremfya |
| Incyte Corporation | $210.50 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $189.86 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $163.43 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $152.08 | 2024-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $148.66 | 2023-2025 | |
| Leo Pharma INC. | $109.06 | 2025 | Adbry, Anzupgo |
| Pfizer INC. | $74.24 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $49.34 | 2025 | |
| Fidia Pharma USA INC. | $45.75 | 2024 | |
| Botanix Sb INC | $37.76 | 2025 | Sofdra |
| Amgen INC. | $36.65 | 2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.24 | 2024 | Jublia, Cabtreo, Arazlo |
| Kyowa Kirin, INC. | $18.84 | 2024 | Poteligeo |
| Verrica Pharmaceuticals INC. | $15.45 | 2023 | Ycanth |
| Merz North America, INC. | $14.86 | 2025 | |
| Journey Medical Corporation | $14.84 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.92 | 2024 | Spevigo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devina Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.